CN109477145B - 炎症性肠病的生物标志物 - Google Patents

炎症性肠病的生物标志物 Download PDF

Info

Publication number
CN109477145B
CN109477145B CN201780041664.4A CN201780041664A CN109477145B CN 109477145 B CN109477145 B CN 109477145B CN 201780041664 A CN201780041664 A CN 201780041664A CN 109477145 B CN109477145 B CN 109477145B
Authority
CN
China
Prior art keywords
ibd
genes
individual
risk
progression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780041664.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109477145A (zh
Inventor
保罗·A·莱昂斯
约恩·F·麦金尼
达妮埃莱·比亚希
詹姆斯·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of CN109477145A publication Critical patent/CN109477145A/zh
Application granted granted Critical
Publication of CN109477145B publication Critical patent/CN109477145B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201780041664.4A 2016-07-05 2017-07-05 炎症性肠病的生物标志物 Expired - Fee Related CN109477145B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1611738.4A GB201611738D0 (en) 2016-07-05 2016-07-05 Biomarkers for inflammatory bowel disease
GB1611738.4 2016-07-05
PCT/IB2017/000997 WO2018007872A1 (en) 2016-07-05 2017-07-05 Biomarkers for inflammatory bowel disease

Publications (2)

Publication Number Publication Date
CN109477145A CN109477145A (zh) 2019-03-15
CN109477145B true CN109477145B (zh) 2021-04-09

Family

ID=56891052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780041664.4A Expired - Fee Related CN109477145B (zh) 2016-07-05 2017-07-05 炎症性肠病的生物标志物

Country Status (15)

Country Link
US (3) US11041206B2 (https=)
EP (1) EP3481964B1 (https=)
JP (2) JP7111630B2 (https=)
KR (1) KR102352847B1 (https=)
CN (1) CN109477145B (https=)
AU (1) AU2017293417B2 (https=)
CA (1) CA3029912A1 (https=)
DK (1) DK3481964T3 (https=)
ES (1) ES2906192T3 (https=)
GB (1) GB201611738D0 (https=)
HU (1) HUE058197T2 (https=)
LT (1) LT3481964T (https=)
PL (1) PL3481964T3 (https=)
PT (1) PT3481964T (https=)
WO (1) WO2018007872A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10515408B2 (en) 2003-08-13 2019-12-24 Bgc Partners, Inc. Systems and methods for bid/offer liquidity spread trading
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
CA3047302C (en) * 2016-12-14 2024-01-02 Tracy WARREN System and methods for developing and using a microbiome-based action component for patient health
US20210338486A1 (en) 2018-10-18 2021-11-04 T.J.Smith And Nephew,Limited Tissue treatment device
GB201817052D0 (en) 2018-10-19 2018-12-05 Smith & Nephew Tissue treatment device
CN110400603A (zh) * 2019-07-23 2019-11-01 中国石油大学(华东) 基于格局加权的ibd矩阵计算方法
GB201912518D0 (en) 2019-08-30 2019-10-16 Cambridge Entpr Ltd Inflammatory disease prognostics
GB202005867D0 (en) 2020-04-22 2020-06-03 Smith & Nephew Tissue treatment device
GB202100527D0 (en) 2021-01-15 2021-03-03 Smith & Nephew Systems and methods for managing operation of wound dressings or wound treatment devices
IL305808A (en) * 2021-03-12 2023-11-01 Janssen Biotech Inc Methods for predicting response to the treatment of ulcerative colitis
CN114517228A (zh) * 2021-12-31 2022-05-20 青岛锐翌精准医学检验有限公司 炎症性肠病标志基因及其应用
CN114645088B (zh) * 2022-04-22 2023-12-15 广东省人民医院 克罗恩病进展风险相关评估基因集、试剂盒、应用和系统
EP4606910A1 (en) * 2024-02-21 2025-08-27 Royal College of Surgeons in Ireland Diagnostic and prognostic methods relating to ulcerative colitis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118851A1 (en) * 2004-06-02 2005-12-15 Diagenic As Oligonucleotides for cancer diagnosis
CN101970689A (zh) * 2007-11-29 2011-02-09 健泰科生物技术公司 炎性肠病的基因表达标志物
CN103025890A (zh) * 2010-04-06 2013-04-03 卡里斯生命科学卢森堡控股 疾病的循环生物标志物
WO2016066288A1 (en) * 2014-10-28 2016-05-06 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for inflammatory bowel disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133287A2 (en) 2005-06-06 2006-12-14 Wyeth Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
GB0610949D0 (en) * 2006-06-02 2006-07-12 Glaxosmithkline Biolog Sa Method
JP2011516492A (ja) * 2008-04-02 2011-05-26 メタプロテオミクス， エルエルシー 内皮炎症及び内皮−単球相互作用の置換１，３−シクロペンタジオンによる減弱
KR100985090B1 (ko) * 2008-05-23 2010-10-04 한국과학기술연구원 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
AU2010207640B2 (en) * 2009-01-20 2016-09-08 Cambridge Enterprise Limited Methods for predicting autoimmune disease risk
EP2419532A1 (en) * 2009-04-17 2012-02-22 Université Libre de Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
EP2272977A1 (en) 2009-07-08 2011-01-12 Universite Libre De Bruxelles Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
EP2678448A4 (en) 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management
SG11201402490XA (en) 2011-11-23 2014-06-27 Amgen Inc Methods of treatment using an antibody against interferon gamma
CA2867118A1 (en) 2012-03-13 2013-09-19 Baylor Research Institute Early detection of tuberculosis treatment response
EP2904405B1 (en) 2012-10-05 2017-05-31 Nestec S.A. Methods for predicting and monitoring mucosal healing
WO2014093872A1 (en) 2012-12-13 2014-06-19 Baylor Research Institute Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
CN105683392A (zh) * 2013-03-15 2016-06-15 博德研究所 树突细胞应答基因表达、物质组合物及其使用方法
WO2015120382A1 (en) * 2014-02-07 2015-08-13 The Johns Hopkins University Predicting response to epigenetic drug therapy
WO2015148809A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
WO2016138488A2 (en) * 2015-02-26 2016-09-01 The Broad Institute Inc. T cell balance gene expression, compositions of matters and methods of use thereof
US20180305689A1 (en) 2015-04-22 2018-10-25 Mina Therapeutics Limited Sarna compositions and methods of use
US20170003277A1 (en) * 2015-07-01 2017-01-05 Michael Hayden Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118851A1 (en) * 2004-06-02 2005-12-15 Diagenic As Oligonucleotides for cancer diagnosis
CN101970689A (zh) * 2007-11-29 2011-02-09 健泰科生物技术公司 炎性肠病的基因表达标志物
CN103025890A (zh) * 2010-04-06 2013-04-03 卡里斯生命科学卢森堡控股 疾病的循环生物标志物
WO2016066288A1 (en) * 2014-10-28 2016-05-06 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for inflammatory bowel disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A CD8+ T cell transcription signature predicts prognosis in autoimmune disease;Eoin F McKinney等;《Nature Medicine》;20100418;第16卷(第5期);586-591 *
血清标志物对炎症性肠病诊断和预后评判应用进展;唐颢等;《中国实用内科杂志》;20150930;第35卷(第9期);794-797 *

Also Published As

Publication number Publication date
CN109477145A (zh) 2019-03-15
US10640829B2 (en) 2020-05-05
AU2017293417B2 (en) 2019-11-14
LT3481964T (lt) 2022-04-11
DK3481964T3 (da) 2022-02-07
KR20190025637A (ko) 2019-03-11
WO2018007872A9 (en) 2018-03-15
US20180010187A1 (en) 2018-01-11
PT3481964T (pt) 2022-02-17
ES2906192T3 (es) 2022-04-13
US11041206B2 (en) 2021-06-22
EP3481964A1 (en) 2019-05-15
US20180010189A1 (en) 2018-01-11
NZ750396A (en) 2020-12-18
PL3481964T3 (pl) 2022-04-11
US10202651B2 (en) 2019-02-12
HUE058197T2 (hu) 2022-07-28
GB201611738D0 (en) 2016-08-17
CA3029912A1 (en) 2018-01-11
JP7111630B2 (ja) 2022-08-02
EP3481964B1 (en) 2021-12-29
JP2020198884A (ja) 2020-12-17
JP2019527039A (ja) 2019-09-26
WO2018007872A1 (en) 2018-01-11
US20190032140A1 (en) 2019-01-31
AU2017293417A1 (en) 2019-02-21
KR102352847B1 (ko) 2022-01-17

Similar Documents

Publication Publication Date Title
CN109477145B (zh) 炎症性肠病的生物标志物
US10260097B2 (en) Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
US11091809B2 (en) Molecular diagnostic test for cancer
US10851415B2 (en) Molecular predictors of sepsis
AU2016228508A1 (en) Methods for diagnosis of sepsis
EP3430172A1 (en) Methods of diagnosing inflammatory bowel disease through rnaset2
AU2012261820A1 (en) Molecular diagnostic test for cancer
US10793911B2 (en) Host DNA as a biomarker of Crohn's disease
US20240247315A1 (en) Diagnosing inflammatory bowel diseases
EP3146076A2 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
HK40003433B (en) Biomarkers for inflammatory bowel disease
HK40003433A (en) Biomarkers for inflammatory bowel disease
HK40007518B (en) Biomarkers for inflammatory bowel disease
NZ750396B2 (en) Biomarkers for inflammatory bowel disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003433

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210409

CF01 Termination of patent right due to non-payment of annual fee